Comprehensive Myeloid & Lymphoid Panel is a next-generation sequencing (NGS)-based test designed to detect a wide range of clinically relevant genetic alterations associated with myeloid and lymphoid malignancies. The test analyses DNA and RNA extracted from peripheral blood or bone marrow samples to provide a detailed molecular profile of the patient’s leukemia. By consolidating multiple conventional tests into a single, high-throughput assay, the panel delivers comprehensive information to support diagnosis, risk stratification, therapy selection, and minimal residual disease (MRD) monitoring.
| Myeloid Malignancies | Fusions | Point Mutations |
|---|---|---|
| AML: Acute Myeloid Leukemia | T(8;21); RUNX1T1-RUNX1 t(15;17); PML-RARA t(11q23) rearrangement: MLL (KMT2A) inv(16); CBFB-MYH11 t(9;11); MLLT3-MLL (KMT2A) t(6;9); DEK-NUP214 t(9;12); ETV6-MECOM AML (megakaryoblastic) with t(1;22) RBM15-MKL1. | ASXL1, KIT, FLT3 (ITD and TKD), NPM1, GATA2, MECOM, CEBPA, IDH1, IDH2, NRAS, TP53 |
| MPN: Myeloproliferative Neoplasm | t(9;22); BCR-ABL1. | JAK2, MPL, and CALR; ASXL1, EZH2, TET2, IDH1, IDH2, TP53, SRSF2 |
| MDS: Myelodysplastic Syndromes | Del 5q, Del 7q, Del 20q, Trisomy 8, Inv 3. | SF3B1, TET2, SRSF2, ASXL1, RUNX1, TP53, U2AF1, DNMT3A, EHZ2 |
| CML: Chronic Myelogenous Leukemia | t(9;22); BCR-ABL1. | ASXL1, RUNX1, IDH1/2, JAK2, SRSF2, TP53, BRAF, CDKN2A/B, CBLC, CBLB, CRLF2, CREBBP |
| JMML: Juvenile Myelomonocytic Leukemia | PTPN11, JAK2, NRAS, KRAS, CBL, NF1 | |
| B-ALL | Paediatric: t(12;21); ETV6-RUNX1, t(9;22); BCR-ABL1, t(1;19); E2A-PBX1 (previously MLL) translocations. In adults: t(9;22); BCR-ABL1, rearrangement MYC, iAMP21, trisomy 4 and 10. | ABL1, TET2, CDKN2A, CREBBP, NRAS, KRAS, NOTCH1, JAK2, KDM6A, IKZF1, PAX5, TP53. |
| T-ALL | DNMT3A, NRAS, KRAS, NOTCH1, NRAS, FBXW7, PTEN, RUNX1, CDKN2B, FBXW7 | |
| Ph-like ALL | BCR-ABL1, ETV6-RUNX1, KMT2A, CRLF2 rearrangement; fusions involving JAK-STATPathway, ABL-class genes | |
| CLL | del (11q), del (13q), del (6q), trisomy 12 and del (17p). | MYD88, NOTCH1, TP53, BIRC3, SF3B1, IGHV mutation. TP53 sequencing, BTK and PLCG2 for ibrutinib resistance. |
Detects: 600+ Fusions, SNVs & InDels in 133 genes & CNVs. All myeloid and lymphoid malignancies are covered.
TAT: 12 working days
Test Code: MGM2450
Detects: SNVs & InDels in 133 genes, CNVs in clinically relevant genes. All myeloid and lymphoid malignancies are covered.
TAT: 12 working days
Test Code: MGM499
Detects: 600+ Fusions.
All myeloid and lymphoid malignancies are covered in this test.
TAT: 10 working days
Test Code: MGM1824
Detects: SNVs and InDels in 130+ genes.
TAT: 14 working days
Test Code: MGM2534
Detects: MRD in fusion-positive leukemia.
TAT: 14 working days
Test Code: MGM2603
Detects: 26 genes (SNVs/InDels) | 8 genes (Fusions / Translocations).
TAT: 7 working Days
Test Code:MGM3514
Detects: 20 genes (SNVs/InDels and CNVs) | 15 genes (Fusions / Translocations).
TAT: 7 working Days
Test Code:MGM3586
Detects: MRD detection in NPM1 (Nucleophosmin 1) mutated AML (Acute Myeloid Leukemia).
TAT: 3 working days
Test Code: MGM3650
TAT: 5 working days
Test Code: MGM3663
Detects SNVs, InDels, CNVs, and all cryptic/acryptic gene fusions in one test, reducing the need for multiple assays like FISH or RT-PCR.
98% sensitivity and specificity, validated per CAP guidelines, with 100% performance in biannual proficiency testing.
Identifies novel fusion partners and cryptic transcripts often missed by conventional methods, essential for targeted therapy planning.
Please share your details to get
in touch with our experts.
